140-82-9 Usage
Uses
1. Chemical Synthesis:
6-Ethyl-3-oxa-6-azaoctanol is used as an intermediate in the synthesis of various chemicals. Its unique chemical structure allows it to be a valuable building block for creating a range of compounds with different applications.
2. Pharmaceutical Industry:
In the pharmaceutical industry, 6-Ethyl-3-oxa-6-azaoctanol is used as a starting material for the development of new drugs. Its chemical properties make it suitable for use in the synthesis of various pharmaceutical compounds, potentially leading to the discovery of novel treatments for various medical conditions.
3. Research and Development:
6-Ethyl-3-oxa-6-azaoctanol is also used in research and development laboratories for studying its chemical properties and potential applications. Scientists and researchers can use this compound to explore new reaction pathways and develop innovative methods for synthesizing other chemicals.
4. Metabolite and Degradation Product Studies:
As a metabolite of Butamirate and a degradation product of Oxeladin citrate (OL) and Oxybutynin hydrochloride (OB), 6-Ethyl-3-oxa-6-azaoctanol is used in studies related to drug metabolism and degradation. This helps researchers understand the metabolic pathways and potential side effects of these drugs, which can be crucial in drug development and safety assessment.
Air & Water Reactions
Highly flammable. Slightly soluble in water.
Reactivity Profile
6-Ethyl-3-oxa-6-azaoctanol is an amine and alcohol. Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.
Health Hazard
Inhalation or contact with material may irritate or burn skin and eyes. Fire may produce irritating, corrosive and/or toxic gases. Vapors may cause dizziness or suffocation. Runoff from fire control may cause pollution.
Fire Hazard
HIGHLY FLAMMABLE: Will be easily ignited by heat, sparks or flames. Vapors may form explosive mixtures with air. Vapors may travel to source of ignition and flash back. Most vapors are heavier than air. They will spread along ground and collect in low or confined areas (sewers, basements, tanks). Vapor explosion hazard indoors, outdoors or in sewers. Runoff to sewer may create fire or explosion hazard. Containers may explode when heated. Many liquids are lighter than water.
Safety Profile
A poison by ingestion
and skin contact. A severe eye and mdd skin
irritant. When heated to decomposition it
emits toxic vapors of NOx.
Check Digit Verification of cas no
The CAS Registry Mumber 140-82-9 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,4 and 0 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 140-82:
(5*1)+(4*4)+(3*0)+(2*8)+(1*2)=39
39 % 10 = 9
So 140-82-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H19NO2/c1-5-9(6-2)7(3)11-8(4)10/h7-8,10H,5-6H2,1-4H3
140-82-9Relevant articles and documents
SILICON PHTHALOCYANINE COMPLEX, PREPARATION METHOD AND MEDICINAL APPLICATION THEREOF
-
Paragraph 0122; 0123, (2017/01/26)
The present invention relates to a silicon phthalocyanine complex, the preparation method and the medicinal application thereof. The present invention particularly relates to a silicon phthalocyanine complex of formula (I), the preparation method thereof and a pharmaceutical composition comprising the same, as well as the use thereof as a photosensitizer, in particular the use in the treatment of cancers, wherein each substituent in formula (I) is the same as defined in the description.
High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products
El-Gindy, Alaa
, p. 689 - 699 (2007/10/03)
Two high performance liquid chromatographic (HPLC) methods are presented for the determination of oxeladin citrate (OL) and oxybutynin hydrochloride (OB) and their degradation products. The first method was based on HPLC separation of OL from its degradation product using a Nucleosil C18 column with a mobile phase consisting of acetonitrile -0.1% phosphoric acid (60:40 v/v). The second method was based on HPLC separation of OB from its degradation product using a VP-ODS C18 column with a mobile phase consisting of acetonitrile/0.01:M potassium dihydrogen phosphate/diethylamine (60:40:0.2). Quantitation was achieved with UV detection at 220:nm based on peak area. The two HPLC methods were applied for the determination of OL or OB, their degradation products, methylparaben and propylparaben in pharmaceutical preparations. The proposed methods were used to investigate the kinetics of acidic and alkaline degradation processes of OL and OB at different temperatures and the apparent pseudofirst-order rate constant, half-life and activation energy were calculated. The pH-rate profiles of degradation of OL and OB in Britton-Robinson buffer solutions within the pH range 2-12 were studied.
Methods of enhancing renal uptake of oligonucleotides
-
, (2008/06/13)
2′-O-Modified ribosyl nucleosides and modified methods containing such nucleosidic monomers are disclosed. Methods are disclosed that have increased binding affinity as shown by molecular modeling experiments. Methods are also disclosed for enhancing the renal uptake of oligomeric compounds as shown using a two-step HRP imunohistochemistry assay. The 2′-O-modified nucleosides of the invention include ring structures that position the sugar moiety of the nucleosides preferentially in 3′ endo geometries.
2′-O-aminoethyloxyethyl-modified oligonucleotides
-
, (2008/06/13)
2′-O-Modified ribosyl nucleosides and modified oligomeric compounds containing such nucleosidic monomers are disclosed. Oligomeric compounds are disclosed that have increased binding affinity as shown by molecular modeling experiments. The 2′-O-modified nucleosides of the invention include ring structures that position the sugar moiety of the nucleosides preferentially in 3′ endo geometries.
